Higher levels of Lp(a) are also associated with deep vein thrombosis and pulmonary embolism according to this retrospective cohort study.
Opinion|Videos|April 11, 2025
Advancing Retinal Disease Treatment – The Next Generation of Anti-VEGF Therapies
Listen
0:00 / 0:00
Ehsan Rahimy, MD; David G. Miller, MD, and Jordana Fein, MD, discusses how 8 milligram aflibercept and faricimab, newer anti-VEGF therapies for retinal diseases, offer improved durability with comparable safety profiles to existing treatments, allowing less frequent injections while maintaining equivalent vision outcomes.
Advertisement
Timecodes:
1:25- Rationale for high dose aflibercept
5:00- PULSAR trial for AMD
12:00- PHOTON trial for DME
16:21- Changing practice patterns
22:29- Faricimab and role of ang-2 inhibition
28:30 Impact of new therapies
Advertisement
Related to this article
Donald Cutlip, MD, discusses the sirolimus balloon’s approval and its role in clinical practice for patients with ISR.
Ochsner Transplant Institute director discusses liver transplant care, robotic kidney transplant, organ preservation, and access gaps.
Mirum's antibody led to virologic response and ALT normalization in up to 56% of patients at week 24, vs 0% with delayed treatment.
Murad Alam, MD, and Elizabeth Kiracofe, MD, discuss how reimbursement, coverage, and advocacy shape dermatology access for patients with skin of color.
Stress led all triggers, and a sense of an impending attack was the most reliable prodrome in patients with HAE-C1INH in the US HAEA Scientific Registry.
Stay updated with the latest healthcare breakthroughs, including the FDA approval of insulin efsitora alfa-gobe (Onswik).
Approval is based on 36-week data from BRAVE-AA-PEDS, in which 42% of patients on the 4 mg dose achieved a SALT score of 20 or less, compared with 5% on placebo.
Advertisement
Advertisement
Trending on HCPLive
1
FDA Approves Obinutuzumab (Gazyva) for Idiopathic Nephrotic Syndrome
2
Lessons From 10,000 Organ Transplants, With Ari Cohen, MD
3
Brelovitug Meets Primary Endpoint in Phase 3 AZURE-1 Hepatitis Delta Trial
4
Efsitora Dosing and Titration in Type 2 Diabetes
5